Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: recalling drug products following an FDA inspection.
| Brand name | ARIPIPRAZOLE |
| Generic name | ARIPIPRAZOLE |
| Active ingredient(s) | ARIPIPRAZOLE |
| Distributed by / for | Accord Healthcare, Inc., Durham, NC 27703 |
| NDC | 16729-280-10 |
| Full product label | Aripiprazole Tablets, USP 10 mg Rx Only, Packaged as a) 30-count bottle, NDC 16729-280-10, UPC 3 16729 28010 5; b) 100-count bottle, NDC 16729-280-01, UPC 3 16729 28001 3; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. India |
| Recalling firm | Accord Healthcare, Inc. |
| Distribution | United States including Puerto Rico and Canada |
| Quantity | 539,004 bottles |
| Recall initiated | 2023-02-07 |
| Report date | 2023-03-08 |
| Recall completed | 2024-04-22 |
| Recall number | D-0367-2023 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Durham NC United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗